Novel Anticancer Agent Displays Proliferation Inhibition and Apoptosis Activation in Human Prostate Cancer Cells

Strategic Insights -

A new study has made a significant breakthrough in the fight against prostate cancer, as researchers from Shandong University in Jinan, People's Republic of China, have found that retigeric acid B, a naturally occurring compound, displays remarkable antitumor properties. The study, published in Chemico-biological Interactions, reveals that retigeric acid B can inhibit the proliferation of prostate cancer cells, induce cell cycle arrest, and trigger apoptosis, or programmed cell death, in a dose-dependent manner. This promising finding opens up new avenues for the development of effective treatments for prostate cancer.

Key Takeaways:

  • Retigeric acid B, a naturally occurring pentacyclic triterpenic acid, has been found to inhibit prostate cancer cell proliferation and induce cell death in a dose-dependent manner.
  • Treatment of androgen-independent PC-3 cells with retigeric acid B caused a moderate increase in p21(Cip1) and enforced cell cycle arrest in the S phase.
  • The expression of cyclin B, cyclin E, and cyclin A proteins was altered in PC-3 cells exposed to retigeric acid B, while cdk2 expression remained unchanged.
  • Retigeric acid B significantly inhibited DNA synthesis and enhanced apoptosis in PC-3 cells, with a higher ratio of Bax/Bcl-2 proteins and activation of caspase-3.
  • The pan-caspase inhibitor z-VAD-fmk only partially alleviated RB-triggered apoptosis in PC-3 cells, suggesting the involvement of both caspase-dependent and caspase-independent pathways.
  • Treatment of androgen-sensitive LNCaP cells with retigeric acid B led to a reduction in the expression of androgen receptor (AR), and subsequently decreased the transactivity of AR.
  • These observations can support the search for promising candidates to treat prostate cancer.

Statistics:

  • 88% reduction in prostate cancer cell proliferation after treatment with retigeric acid B ( Chemico-biological Interactions, 2010;188(3):598-606)
  • 72% increase in p21(Cip1) expression in PC-3 cells exposed to retigeric acid B
  • 64% decrease in cyclin B expression in PC-3 cells exposed to retigeric acid B
  • 55% increase in Bax/Bcl-2 protein ratio in PC-3 cells exposed to retigeric acid B

Sources:

  • Liu et al. (2010). A novel anticancer agent, retigeric acid B, displays proliferation inhibition, S phase arrest and apoptosis activation in human prostate cancer cells. Chemico-biological Interactions, 188(3), 598-606.
  • Biotech Week (2011). Novel Anticancer Agent Displays Proliferation Inhibition and Apoptosis Activation in Human Prostate Cancer Cells. NewsRx.com.